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Abstract
Purpose Hyperintensities are common in neuroimaging scans of patients with mild acute focal neurology. However, their
pathogenic role and clinical significance is not well understood. We assessed whether there was an association between
hyperintensity score with diagnostic category and clinical assessments/measures.
Methods One hundred patients (51 ± 12 years; 45:55 women:men), with symptomatology suggestive of short duration ischemia
referred for magnetic resonance imaging, were prospectively recruited in NHS Grampian between 2012 and 2014.
Hyperintensities were quantified, on T2 and FLAIR, using the Scheltens score.
Results The most frequent diagnosis was minor stroke (33%), migraine (25%) and transient ischemic attack (17%). The mean
total Scheltens score was 28.49 ± 11.93 with all participants having various loads of hyperintensities. Statistically significant
correlations between hyperintensity scores and clinical assessments/measures (age, systolic blood pressure, pulse pressure,
MoCA) at the global level were also reflected regionally. These provide further supporting data in terms of the robustness of
the Scheltens scale.
Conclusion Hyperintensities could serve as a diagnostic and prognostic imaging biomarker for patients, presenting with mild
acute focal neurology, warranting application of automated quantification methods. However, larger cohorts are required to
provide a definitive answer especially as this is a heterogenous group of patients.
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Introduction
White matter hyperintensities are frequently observed in neu-
roimaging structural scans of patients with mild acute focal
neurology who are later diagnosed with minor stroke, tran-
sient ischemic attack (TIA), migraine or a functional neuro-
logical disorder. However, their underlying pathogenic role
and clinical significance [1, 2], especially in this patient group
(or type), has not been fully explained. A better insight into
this has the potential not only to aid the diagnostic process and
immediate management plans, considering the challenges for
diagnosing patients with mild acute focal neurology, but also
to inform risk predictor models of recurring focal neurology
along with quantifying future functional and cognitive
outcomes.
The Scheltens scale is a visual rating scale that describes
the anatomical distribution of hyperintensities and quantifies
their amount (total number and size of each hyperintensity)
providing information at the global and regional levels [3, 4].
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We assessed whether there was a difference in the total
Scheltens score and different diagnostic categories along with
ascertaining the observed power to inform future study de-
signs. We also assessed whether there was an association be-
tween total and individual hyperintensity scores—and various
clinical assessments/measures as described in the
Supplementary File. The purpose was to explore whether sta-
tistically significant results relating to global changes were
reflected at a regional level with any patterns of clinical
relevance.
Methods
One hundred patients, with a mean age of 51 ± 12 years and a
45:55 women to men ratio, with mild acute focal neurology
consistent with a diagnosis of short duration ischemia [5, 6]
referred for magnetic resonance imaging (MRI) were prospec-
tively enrolled in NHS Grampian between 2012 and 2014.
Imaging data were acquired on a 3.0 Tesla Philips Achieva
scanner (Philips Healthcare, Best, The Netherlands; http://
www.philips.com/global/index.page) with a Siemens 32-
channel coil (Siemens Medical Systems, Iselin, NJ; http://
www.healthcare.siemens.co.uk). Hyperintensities were
assessed on axial T2 and FLAIR scans, by a blinded
assessor, using the Scheltens scale [3, 4].
A one-way ANOVA assessed for any significant differences
in the Scheltens score and different diagnostic categories. The
Pearson’s explored the correlations between the Scheltens scores
and various clinical assessments/measures. The Benjamin-
Hochberg procedure was applied, with a false discovery rate
(FDR) of 0.05, to control for type I errors (false positives) po-
tentially arising from multiple comparisons. Analysis was
performed in SPSS version 25 (IBM Corporation, Armonk,
NY; http://www-01.ibm.com/software/analytics/spss/). Full
methodological details are available in the Supplementary File.
Results
The most frequent diagnosis was minor stroke (33%), follow-
ed by migraine (25%), TIA (17%) and functional neurological
disorders (7%). The remaining 18%were diagnosed as ‘other’
with a full list provided in the Supplementary File. The
ANOVA yielded no statistically significant differences in the
total Scheltens scores and different diagnostic categories
(F[4,95] = 1.177, exact p = 0.326, Adjusted R Squared =
0.007). However, the observed power for this part of the anal-
ysis was 36%. The mean total Scheltens score was 28.49 ±
11.93 with all participants having various loads of
hyperintensities, both globally and regionally, but with no
one having zero hyperintensities at any level (Table 1).
With the Benjamini-Hochberg post hoc correction, the fol-
lowing statistically significant findings emerged. A positive cor-
relation between: (i) age with total Scheltens score (r = 0.550;
p < 0.001), white matter (r = 0.585; p < 0.001), periventricular
(r = 0.467; p < 0.001) and gray matter hyperintensities (r =
0.399; p < 0.001); (ii) systolic blood pressure with total
Scheltens score (r = 0.340; p = 0.001), white (r = 0.309; p =
0.002) and gray matter hyperintensities (r= 0.355; p < 0.001);
(iii) pulse pressure with total Scheltens score (r = 0.325; p =
0.001), white matter (r= 0.352; p < 0.001), periventricular (r =
0.277; p = 0.006), and gray matter hyperintensities (r = 0.245;
p = 0.016); (iv) diastolic blood pressure with gray matter
hyperintensities (r = 0.243; p = 0.017); and (v) cumulative risk
factor score with periventricular hyperintensities (r = 0.271; p =
Table 1 Descriptive statistics of
clinical assessments and
measures*
Assessment/measure Mean ± SD 95% lower–upper CI Min-Max range
Systolic blood pressure 128.33 ± 17.71 124.75–131.92 98–200
Diastolic blood pressure 80.21 ± 10.65 78.05–82.37 50–119
Pulse pressure 48.13 ± 13.03 45.48–50.77 17–94
Modified Rankin Scale (0–6) 0.30 ± 0.61 0.18–0.42 0–4
NIHSS (/42) 0.32 ± 0.73 0.18–0.47 0–3
MoCA (/30) 28.61 ± 1.54 28.27–28.95 23–30
Risk factors score (0–5)** 0.72 ± 1.09 0.50–0.94 0–4
Total Scheltens score (/93) 28.49 ± 11.93 26.12–30.86 6–73
White matter hyperintensities (/30) 9.44 ± 5.94 8.26–10.62 1–30
Periventricular hyperintensities (/9) 4.41 ± 1.66 4.08–4.74 1–9
Gray matter hyperintensities (/30) 8.27 ± 3.86 7.50–9.04 1–21
Infratentorial hyperintensities (/24) 6.36 ± 3.22 5.72–7.00 1–15
*Recorded, and not log transformed, values reported in table
**Calculated from the following past medical history questions: hypertension; hyperlipidemia; diabetes mellitus;
ischemic heart disease; and previous TIA or stroke, with a point was awarded for ‘yes’ answers
CI, confidence interval; SD, standard deviation
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0.006). A negative correlation between the MoCA (MoCaTest,
Québec, Canada, https://www.mocatest.org) and the total
Scheltens score (r = − 0.280; p = 0.012) and white matter
hyperintensities (r = − 0.300; p = 0.007) was also observed.
Discussion
This study provides further data about the potential role of
hyperintensities in patients with mild acute focal neurology.
Although there were no statistically significant differences in the
total Scheltens score and the different diagnostic categories, it is
still of clinical importance that all participants hadhyperintensities
on their scanswith aminimum total score of six and no individual
Scheltens scale components having a zero score (Table 1). The
observed power also suggests that larger cohorts are needed to
provide a definitive answer as to whether different diagnoses are
associated with different hyperintensity loads.
The significant positive correlation between the total
Scheltens score and age is not unexpected, as hyperintensities
become more prevalent with increasing age [1]. However, this
global change was also noted regionally with a significant pos-
itive correlation in age and amount of hyperintensities within
the white and gray matter and around the ventricles. The sig-
nificant negative correlation between MoCA and the total
Scheltens score and white matter scores supports published
literature linking hyperintensities with declining cognitive func-
tion [1]. The links between systolic blood pressure and pulse
pressure with the total Scheltens score and some of its individ-
ual components provide additional information that these pa-
rameters might be involved in their pathogenesis. However, this
is not a straightforward cause-effect relationship and research
suggests that genes, which regulate a variety of biological pro-
cesses, also play a contributing part [2]. These results should be
interpreted with caution, as this is a heterogenous group of
patients with each diagnostic category having different patho-
physiological mechanisms. The correlations were also between
hyperintensity scores and recognised risk factors (age, hyper-
tension) or outcomes (cognition) and the neurological
presentation/diagnosis could have been incidental.
Although the Scheltens scale is a labour-intensive visual
scale, the above findings showed that significant results in
relation to the total score (global changes) were also reflected
at the regional level in individual components of the scale.
These provide further supporting data in terms of its robust-
ness when compared with alternatives. Generally, manual as-
sessment of hyperintensities is not perfect with ceiling effects
and staff/training requirements being potential issues.
Hyperintensities could serve in the future as an additional
imaging biomarker in mild acute focal neurology. However,
further research is required, with larger cohorts, to determine
their exact role in each diagnostic category and automated
quantification will undoubtedly help with standardisation.
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